超声分子靶向造影剂的应用研究进展  

Advances in Molecular Targeted Ultrasound Contrast Agents

作　　者：杨振 张明博 罗渝昆 YANG Zhen;ZHANG Mingbo;LUO Yukun(Department of Ultrasound,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]中国人民解放军总医院第一医学中心超声诊断科,北京100853

出　　处：《中国医学科学院学报》2023年第2期298-302,共5页Acta Academiae Medicinae Sinicae

基　　金：北京市自然科学基金(7152137)。

摘　　要：超声分子靶向造影剂通过外周静脉注射进入血液循环之后,与相应受体结合,增强了目标病灶的成像信号,可实现疾病的早期诊断、分期、疗效评估及靶向治疗等。超声分子靶向造影剂还能通过微泡进行靶向药物或基因递送。纳米级的靶向造影剂还可透过血管内皮进入组织间隙内进行成像或治疗。超声分子靶向造影剂的研究目前多停留在临床前实验阶段,有一些临床试验已经在人体中开展,初步证实了靶向超声造影剂的安全性和可行性,超声分子靶向造影剂具有广阔的临床应用前景。In real-time ultrasound,molecular targeted contrast agent is introduced into the blood circulation through peripheral intravenous injection to enhance the imaging signal of target lesions after binding to the corresponding intravascular receptors,which can realize early diagnosis,staging of diseases,assessment of treatment response,and targeted treatment.In addition,molecular targeted ultrasound contrast agents provide a platform for the delivery of drugs and genes via microbubbles,and nanoscale contrast agents can be infiltrated through vascular endothelium into the interstitial space of the lesion for imaging or treatment.The available studies of molecular targeted ultrasound contrast agents mainly focus on the preclinical trials.Some clinical trials have been conducted in humans and preliminarily confirm the safety and feasibility of targeted ultrasound contrast agents.The molecular targeted ultrasound contrast agents enjoy a broad prospect in clinical application.

关 键 词：超声分子影像 靶向造影剂 诊断 疗效评估 药物递送 

分 类 号：R445.1[医药卫生—影像医学与核医学]